OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	76
Therapeutic development and current uses of BCL-2 inhibition	64
Bispecifics, trispecifics, and other novel immune treatments in myeloma	38
Platelet transfusion refractoriness: how do I diagnose and manage?	38
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	37
Monoclonal gammopathies of clinical significance	34
Updates in infection risk and management in acute leukemia	34
Preventing infections in children and adults with asplenia	34
Management of AL amyloidosis in 2020	32
Therapy for lower-risk MDS	30
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	29
Gene therapy for hemophilia	26
Inferior vena cava filters: a framework for evidence-based use	25
Next-generation cell therapies: the emerging role of CAR-NK cells	25
Updates in chronic graft-versus-host disease	23
Management of Waldenström macroglobulinemia in 2020	23
Outpatient transfusions for myelodysplastic syndromes	22
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	22
Have we reached a molecular era in myelodysplastic syndromes?	22
Does ABO and RhD matching matter for platelet transfusion?	21
Advances in the management of α-thalassemia major: reasons to be optimistic	21
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	21
Future of CAR T cells in multiple myeloma	21
Combining antiplatelet and anticoagulant therapy in cardiovascular disease	20
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	20

Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	19
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	19
Dyskeratosis congenita and telomere biology disorders	18
Gene therapy for sickle cell disease: where we are now?	18
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	18
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	17
What to use to treat AML: the role of emerging therapies	17
Allogeneic hematopoietic cell transplantation for older patients	17
Identifying potential germline variants from sequencing hematopoietic malignancies	16
Modern management of Fanconi anemia	16
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	16
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	16
Antibodies and bispecifics for multiple myeloma: effective effector therapy	15
Management of heavy menstrual bleeding on anticoagulation	15
High-risk multiple myeloma: how to treat at diagnosis and relapse?	15
Approach to the patient with suspected hypereosinophilic syndrome	15
Optimizing the management of chronic pain in sickle cell disease	15
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	15
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	14
Does aspirin prevent venous thromboembolism?	14
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	14
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	14
Challenges in chronic transfusion for patients with thalassemia	14
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	14
Epidemiology and treatment of priapism in sickle cell disease	14
Double-hit lymphoma: optimizing therapy	14
Women and bleeding disorders: diagnostic challenges	13
Blast and accelerated phase CML: room for improvement	13
How to recognize and manage COVID-19-associated coagulopathy	13
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	13
Chemotherapy-free frontline therapy for CLL: is it worth it?	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
Indications for transfusion in the management of sickle cell disease	13
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	13
How do we sequence therapy for marginal zone lymphomas?	13
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	12
Transformed lymphoma: what should I do now?	12
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	12
How to manage CML patients with comorbidities	12
Hemophilia gene therapy: ushering in a new treatment paradigm?	12
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	12
Extrahematopoietic manifestations of the short telomere syndromes	11
Diamond-Blackfan anemia	11
Heparin-induced thrombocytopenia and cardiovascular surgery	11
Inherited microcytic anemias	11
Global look at nutritional and functional iron deficiency in infancy	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11
Cellular therapy for multiple myeloma: what's now and what's next	11
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	11
COVID-19 and thrombosis: searching for evidence	11

β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	11
Lower risk but high risk	10
Sequencing multiple myeloma therapies with and after antibody therapies	10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?	10
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	10
Genomics of MPN progression	10
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	10
Achieving MRD negativity in AML: how important is this and how do we get there?	10
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	10
Direct oral anticoagulant (DOAC) interference in hemostasis assays	10
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	10
When does a PNH clone have clinical significance?	9
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	9
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy	9
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	9
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	9
Novel targets in aggressive lymphoma	9
CAR T cells vs allogeneic HSCT for poor-risk ALL	9
How immunodeficiency can lead to malignancy	9
Hematology 2022—what is complete HLA match in 2022?	9
Molecular prognostication in Ph-negative MPNs in 2022	9